Medicine

Digital health (Ref: Global Digital Health Innovation 2023)

PUBLISHED IN News in Review: APRIL 2024

Back to search

The background

Clinical strength is an assessment of a digital health solution’s rigour, reliability, and validation with respect to clinical applications and outcomes. Measuring clinical strength in digital health involves a comprehensive approach, including scientific validation, regulatory compliance, accuracy, interoperability, user-friendliness, data security, and ongoing monitoring and improvement processes. Driving factors include:

Getting up to speed – what’s new in this article

The regulatory landscape for digital health is becoming increasingly favourable across the globe, with the FDA releasing the Digital Health Policy Navigator in January 2022 and the German DiGA program growing to over 50 successful applications.

There is a growing body of evidence that shows that digital health interventions can be effective in improving health outcomes.

There is growing demand from healthcare providers and payers for evidence-based digital health solutions.

Investors are favouring ventures with evidence.

Medicine

References for this Article

Other Recommended Reading

Clinical Strength in Digital Health

Life Sciences Researcher

Chris Kallos is a highly qualified life sciences professional with a wealth of knowledge and experience, and has been an equity research analyst for over 25 years. His diverse educational background, as well as his international financial services experience, gives him unique insights across the pharmaceuticals and financial services industries – a complex but increasingly interconnected landscape.

Chris earned his Bachelor of Pharmacy from the University of Sydney, and went on to build a successful community pharmacy practice. These years provided him with a solid commercial foundation and valuable hands-on experience in the Australian healthcare sector.

Building upon this real-world healthcare business experience, Chris completed a Master of Business Administration at the Australian Graduate School of Management (University of New South Wales), and then obtained a Master of Applied Finance from Macquarie University. Chris went on to achieve the Chartered Financial Analyst (CFA) designation, a globally recognised certification for investment professionals who are committed to maintaining the highest standards of integrity and professionalism in the financial industry. He is also a Graduate of the Australian Institute of Company Directors (AICD), the world’s largest non-profit membership organisation for directors.

Chris keeps a keen eye on the continuing evolution of the life sciences industry and is committed to helping bridge the information gap between pharmaceuticals, business strategy and finance. He is focused on ongoing education and professional development in order to stay at the forefront of industry trends and best practices.